RNA, U6 small nuclear 335, pseudogeneGenealiases: []
Q-omics provides the consensus-scored RNU6-335P profile across patient tissues and cancer cell-line models. RNU6-335P expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in ESCA. Among the 18 cancer types available for tumor–normal comparison, RNU6-335P is differentially expressed in 3, with the highest sampling consensus in ESCA. Additionally, RNU6-335P RNA expression shows 9,179 significant gene co-expression associations, with the highest sampling consensus in LAML. Together, these results highlight ESCA, and LAML as cancer lineages where RNU6-335P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNU6-335P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNU6-335P survival associations across molecular data types. RNU6-335P RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNU6-335P RNA expression–survival associations across cancer types. High RNU6-335P expression shows unfavorable associations in DLBC, KICH, LGG, OV and UVM, but favorable associations in ESCA. The ESCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify ESCA as the clearest survival context for RNU6-335P RNA expression.
This table summarizes RNU6-335P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for RNU6-335P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNU6-335P shows lower tumor expression in ESCA and THCA and higher tumor expression in KICH. The ESCA box plot shows higher RNU6-335P RNA expression in normal versus tumor tissue (log2 FC = −0.566, t-test p = .034).
This table shows molecular features associated with RNU6-335P in patient tissues and cancer cell lines. In patient samples, RNU6-335P shows the broadest associations at the RNA and protein expression levels, with LAML recurring as the lineage with the largest associated feature set.
